Work

Abstract 1319: Luminal reprogramming, druggable mitogenic pathway activation, and rare outgrowth of occult basal cancers define ER loss in HR+/HER2- MBC

Year: 2025

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2025-1319

Authors: Nolan Priedigkeit, Stefania Morganti, Alinés Lebrón-Torres, Kalie Smith, Melissa E. Hughes, Busem Binoga Kurt, Yvonne Y. Li, Hersh Gupta, Heather A. Parsons, Daniel L. Abravanel, Rinath M. Jeselsohn, Elizabeth A. Mittendorf, Adrian V. Lee, Steffi Oesterreich, Sara M. Tolaney, Andrew D. Cherniack, Nancy U. Lin, Ana C. Garrido-Castro

Institutions: Dana-Farber Cancer Institute, Broad Institute, Brigham and Women's Hospital, University of Pittsburgh, Harvard University

Language: English

Topic: Breast Cancer Treatment Studies

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4409689202

Cites:

Cited by:

Related to: 10